STOCK TITAN

Angiodynamics - ANGO STOCK NEWS

Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.

Overview

AngioDynamics Inc is a Nasdaq-listed public company renowned for designing, manufacturing, and selling a broad portfolio of innovative medical devices that serve diverse clinical applications. With deep expertise in the fields of oncology, interventional radiology, and vascular surgery, the company focuses on the minimally invasive treatment of diseases such as peripheral vascular disorders and cancer. Industry-specific keywords such as "minimally invasive procedures", "diagnostic devices", and "interventional radiology" underscore the company’s commitment to technological innovation.

Core Business and Operations

The company operates by providing a comprehensive range of devices which include systems for radiofrequency ablation, vascular access, angiographic procedures, dialysis support, angioplasty, drainage, thrombolysis, embolization, and venous treatments. These products are designed for use in clinical settings by interventional radiologists, surgeons, and nephrologists. Through its diverse product line, AngioDynamics is able to offer end-to-end solutions that enhance procedural efficiency and patient outcomes. The revenue model primarily relies on direct sales to healthcare institutions, supported by a strong service network ensuring reliability and continued product support.

Market Position and Competitive Landscape

AngioDynamics has distinguished itself in a technologically competitive and high-growth industry. By investing in research and development, the company has maintained its ability to continuously bring forward new technologies and improve existing products. This commitment to innovation positions the company among notable competitors in the medical device industry. Its competitive differentiation stems from a consistent track record of product innovation, robust clinical performance, and strategic market presence. The company's market position is further bolstered by its focused approach to addressing specialized clinical needs and its ability to integrate advanced technological solutions into traditional treatment paradigms.

Product Portfolio and Technological Innovation

The product portfolio of AngioDynamics spans a wide range of medical device categories. From advanced radiofrequency ablation systems to precision surgical tools, the company leverages cutting-edge technology to develop devices that offer improved safety profiles and enhanced procedural outcomes. Emphasis on 'innovative technology' and 'minimally invasive procedures' highlights the company’s pursuit of excellence in device performance. Each product category is built on comprehensive clinical insights and a deep understanding of procedural requirements, ensuring that healthcare providers are equipped with devices that cater to their diagnostic and therapeutic needs.

Operational Excellence and Industry Expertise

AngioDynamics demonstrates operational excellence by aligning its product development with the evolving needs of healthcare providers. The company’s strategic focus on clinical innovation and rigorous quality control reflects its deep industry expertise and commitment to delivering reliable and effective medical solutions. Structured research programs, continuous product improvements, and a robust post-market support system underpin the company’s reputation for innovation and operational excellence. This integrated approach assists healthcare professionals in achieving improved outcomes while ensuring safety and compliance under constantly evolving medical standards.

Strategic Business Model and Value Proposition

Central to AngioDynamics' value proposition is the delivery of solutions that advance the standard of care in critical clinical procedures. The company’s business model is built around the continuous enhancement of product performance and the facilitation of minimally invasive therapeutic options. By maintaining a deep focus on quality and usability, AngioDynamics provides a reliable partnership for medical institutions seeking to integrate innovative device technologies. This strategic alignment with frontline clinical needs makes the company a noteworthy reference point for discussions on medical innovation, procedural efficiency, and enhanced patient care.

Industry Impact and Long-Term Relevance

With a rich history dating back to its founding in 1988, AngioDynamics has consistently contributed to medical advancements through its innovative product solutions. The company's impact on the healthcare industry is visible across multiple clinical areas, reinforcing its role as a significant player in medical technology. The enduring relevance of its products and the clarity of its market focus ensures that AngioDynamics remains a principal component in the discussion of medical device innovation and procedural technology. This comprehensive approach, combined with clear communication and expert-driven design, continues to shape the narrative around modern, efficient, and effective clinical practices.

Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, and EVP and CFO, Stephen Trowbridge, will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 11, 2024. The presentation will focus on the company's medical technology innovations and cancer treatment advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) will report financial results for Q2 of fiscal year 2024 on January 5, 2024. The management will host a conference call to discuss the results, accessible via phone or webcast. The webcast replay and call recording will also be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) has completed the patient enrollment in the APEX-AV study, evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for treating acute intermediate-risk pulmonary embolism (PE). The study enrolled 122 patients across 25 hospital-based sites in the US, with a focus on reducing thrombus burden and improving right ventricular function. The primary efficacy and safety endpoints of the study are the reduction in RV/LV ratio and the rate of Major Adverse Events (MAEs) within the first 48 hours post-procedure. The study aims to broaden the treatment options for PE, which affects around 900,000 people in the US every year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
none
Rhea-AI Summary
AngioDynamics, Inc. reports Q1 FY2024 financial results with net sales of $78.7 million, a 5.7% increase excluding Dialysis and BioSentry sales. Med Tech net sales increased 13.3% to $25.9 million. Gross margin declined 20 basis points to 50.9% on a pro-forma basis. Completed sale of Dialysis and BioSentry businesses for $100 million. Adjusted loss per share of $0.12. Cash and cash equivalents at $57.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
AngioDynamics, Inc. will report Q1 FY2024 financial results on October 4, 2023, before market open. Conference call scheduled at 8:00 a.m. ET to discuss results. Webcast available on company website. Recording of call available until October 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences earnings
-
Rhea-AI Summary
AngioDynamics receives FDA Breakthrough Device designation for AngioVac System's non-surgical removal of vegetation from the right heart.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) to participate in fireside chat at Canaccord Genuity 43rd Annual Growth Conference. The company's President and CEO, Jim Clemmer, and CFO, Stephen Trowbridge, will discuss the latest developments in medical technology and cancer treatment options. The live webcast will be accessible through the 'Investors' section of the company's website at www.angiodynamics.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
-
Rhea-AI Summary
AngioDynamics, Inc. has announced the appointment of Lorinda Burgess to its Board of Directors. Ms. Burgess brings over 35 years of management and financial experience, including over 15 years at Medtronic, Inc. She has a track record of driving growth and profitability through transformative strategies. AngioDynamics aims to become a profitable, high-growth medical technology company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags

FAQ

What is the current stock price of Angiodynamics (ANGO)?

The current stock price of Angiodynamics (ANGO) is $9.46 as of April 16, 2025.

What is the market cap of Angiodynamics (ANGO)?

The market cap of Angiodynamics (ANGO) is approximately 385.6M.

What does AngioDynamics specialize in?

AngioDynamics specializes in designing, manufacturing, and selling a diverse range of medical, surgical, and diagnostic devices used to treat peripheral vascular diseases, oncology cases, and in various surgical settings.

How does AngioDynamics generate its revenue?

The company generates revenue primarily through direct sales of its advanced medical devices and systems to healthcare institutions, predominantly in the United States market.

What are the key product categories offered by AngioDynamics?

Their portfolio includes devices for radiofrequency ablation, vascular access, angiographic procedures, dialysis, angioplasty, drainage, thrombolysis, embolization, and venous treatments, all geared toward minimally invasive procedures.

How does AngioDynamics differentiate itself from competitors?

AngioDynamics differentiates itself through continuous technological innovation, a broad and specialized product line, and a strong focus on meeting the unique procedural needs of healthcare providers.

Who are the primary customers of AngioDynamics?

The primary customers include interventional radiologists, surgeons, and nephrologists who use their devices in hospitals, clinics, and specialized health facilities for treatment procedures.

What is the significance of minimally invasive procedures in their product development?

Minimally invasive procedures are a cornerstone of AngioDynamics' strategy, as they allow for safer, more efficient treatments that improve patient outcomes while reducing recovery times.

How does the company maintain its industry expertise?

Through consistent investment in research and development, rigorous clinical validation, and a commitment to evolving its products based on healthcare provider feedback, AngioDynamics maintains its strong reputation in the industry.

What role does innovation play in AngioDynamics' business model?

Innovation is critical to AngioDynamics, driving the continuous improvement of their product lines and ensuring that they provide cutting-edge solutions for evolving clinical challenges in the medical field.
Angiodynamics

Nasdaq:ANGO

ANGO Rankings

ANGO Stock Data

385.56M
38.33M
5.62%
84.63%
4.24%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LATHAM